.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC07_Frovatriptan.Frovatriptan .Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC07_Frovatriptan.Frovatriptan| name: | Frovatriptan |
| ATC code: | N02CC07 | route: | oral |
| n-compartments | 2 |
Frovatriptan is a selective serotonin (5-HT1B/1D) receptor agonist in the triptan class, used for the acute treatment of migraine attacks with or without aura in adults. It is approved for use in several countries for migraine relief.
Pharmacokinetic parameters reported in healthy adult volunteers (both sexes, age 18-65), after single oral dose administration.
Zheng, H, et al., & Fan, H (2021). Pharmacokinetic Study of Frovatriptan Succinate Tablet After Single and Multiple Oral Doses in Chinese Healthy Subjects. Drug design, development and therapy 15 2961–2968. DOI:10.2147/DDDT.S308958 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34262261
Eiland, LS, & Hunt, MO (2010). The use of triptans for pediatric migraines. Paediatric drugs 12(6) 379–389. DOI:10.2165/11532860-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21028917
Jhee, SS, et al., & Cutler, NR (2001). Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clinical pharmacokinetics 40(3) 189–205. DOI:10.2165/00003088-200140030-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11327198